EyePromise Restore
Commercial- Indications
- Age-related macular degeneration
Company intelligence / Profile preview
ZeaVision’s EyePromise products have been clinically studied for their effects on visual function in early AMD patients. Clinical trials such as the Zeaxanthin and Visual Function Trial demonstrated improvements in driving skills, reading ability, reduction of blind spots, and fine detail discernment after supplementation with zeaxanthin. Over forty million doctor-recommended doses have been consumed safely. The company also supports research into nutritional interventions for diabetic retinopathy.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ZeaVision.